As of November 6, 2026, Biomarin Pharmaceutical Inc. is a publicly traded company (Nasdaq: BMRN); its largest reported holder is BlackRock, with 10% on Schedule 13G/A of November 4, 2026, then Primecap Management Co. (8.24%). The largest insider holding is Alexander Hardy, the chief executive and a director, with 214,635 shares (0.11% of shares outstanding), per Form 4 of March 19, 2026 (Schedule 13G/A, November 4, 2026).
Is this your company?
About to sign with, pay or invest in Biomarin Pharmaceutical Inc.? See the free Snapshot first.
Free to see. No signup.
Is Biomarin Pharmaceutical Inc. a real, registered company?
- Biomarin Pharmaceutical Inc files with the SEC under CIK 1048477 (its SEC filings).
- Its shares are listed under the ticker BMRN on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Novato, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under BIOMARIN PHARMACEUTICAL INC in our court records and SEC 8-K records (as of 2026-11-06).
- Layoffs: 1 state WARN notice (latest 2026-09-24, Novato CA, 117 employees).
- Leadership changes: the latest reported is Robert Plenge (Form 8-K filed 2026-09-14). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names BlackRock (filed 2026-11-04).
Who are Biomarin Pharmaceutical Inc.'s owners and officers?
Biomarin Pharmaceutical Inc.: incorporated in Delaware; business address in Novato, California; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-11-04).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-11-04 | Blackrock, Inc. | 10% |
| Schedule 13G, 2026-04-29 | Vanguard Capital Management | 5.25% |
| Schedule 13G/A, 2026-03-26 | The Vanguard Group | 0% |
| Schedule 13G/A, 2026-01-21 | Blackrock, Inc. | 9.1% |
| Schedule 13G/A, 2025-11-14 | Viking Global Investors LP | 4.3% |
| Schedule 13G/A, 2025-08-14 | Primecap Management Co/Ca/ | 8.24% |
| Schedule 13G/A, 2025-08-14 | Viking Global Investors LP | 6.4% |
Questions about who owns Biomarin Pharmaceutical Inc.
Who owns Biomarin Pharmaceutical Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Biomarin Pharmaceutical Inc.: Blackrock, Inc. (10%, Schedule 13G/A, filed 2026-11-04), Primecap Management Co/Ca/ (8.24%, Schedule 13G/A, filed 2025-08-14) and Vanguard Capital Management (5.25%, Schedule 13G, filed 2026-04-29).
Who are the largest shareholders of Biomarin Pharmaceutical Inc.?
By the share each holder's latest filing reports, the largest holders of Biomarin Pharmaceutical Inc. on this page are Blackrock, Inc. (10%), Primecap Management Co/Ca/ (8.24%) and Vanguard Capital Management (5.25%).
When did Blackrock, Inc. buy into Biomarin Pharmaceutical Inc.?
The filings give report dates, not purchase dates. The earliest filing from Blackrock, Inc. on this page is the Schedule 13G/A, filed 2026-01-21, reporting 9.1%; its latest, Schedule 13G/A filed 2026-11-04, reports 10%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Biomarin Pharmaceutical Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Biomarin Pharmaceutical Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Biomarin Pharmaceutical Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
16 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-09-14 | Robert Plenge | appointed | 2026-09-10 |
Which insiders own Biomarin Pharmaceutical Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and a director: 214,635 shares (0.11% of shares outstanding) (Form 4, 2026-03-19).
- , a director: 126,926 shares (0.07% of shares outstanding) (Form 5, 2026-02-13).
- , the chief financial officer and executive vice president: 123,314 shares (0.06% of shares outstanding) (Form 4, 2026-03-19).
- , the executive vice president and chief technical officer: 84,140 shares (0.04% of shares outstanding) (Form 4, 2026-03-19).
- , the executive vice president and chief legal officer: 61,003 shares (0.03% of shares outstanding) (Form 4, 2026-09-03).
Shares outstanding: 193,694,734 as of 2026-10-26, from the company's latest SEC cover page.
How much has Biomarin Pharmaceutical Inc. raised?
Acquisitions reported on Form 8-K, Item 2.01: completed an acquisition (2026-04-27).
Keep reading
More on Biomarin Pharmaceutical Inc. and the records around it.
Biomarin Pharmaceutical Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Leadership changes Sep 2026
Companies that share a holder
- PRIMECAP MANAGEMENT CO/CA/ also filed stake reports on 24 other companies: Xencor Inc (Nov 2026), GRAIL, Inc. (Nov 2026), MARKETAXESS HOLDINGS INC (Nov 2026)
- VIKING GLOBAL INVESTORS LP also filed stake reports on 27 other companies: City Therapeutics, Inc. (Oct 2026), MID AMERICA APARTMENT COMMUNITIES INC. (Oct 2026), REGAL REXNORD CORP (Sep 2026)
- Vanguard Capital Management also filed stake reports on 1495 other companies: A10 Networks Inc (Oct 2026), Altisource Portfolio Solutions SA (Oct 2026), Alto Neuroscience Inc (Oct 2026)
Related pages
LayoffsLeadership changes5%+ holders
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/biomarin-pharmaceutical